Marksans Pharma completes acquisition of QliniQ B.V.

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

MARKSANS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.3%Reaction day

₹249.75

prior close

₹247.60

announcement price

In-mkt

timing

Nifty Microcap 250market+0.6%-1.9% vs market

Pharmaceuticals peers, median of 164sector-0.2%-1.2% vs sector

On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.1

15m

-0.0

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.3+0.6-1.9-0.2-1.2

Next day

+2.1+1.7+0.4-0.3+2.4

+4.7+2.1+2.6+0.5+4.2

+3.7+3.0+0.7+0.5+3.2

+2.7+3.8-1.1+1.4+1.4

+6.2+3.1+3.1+1.7+4.5

+3.3+2.4+0.9+1.2+2.1

15d

+5.7+1.3+4.4+2.2+3.5

+10.1+3.9+6.2+4.7+5.3

+32.3+7.4+24.9+2.7+29.6

+26.6+5.6+21.0+6.5+20.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Marksans Pharma has completed the process of acquiring 100% share capital of QliniQ B.V., a Netherlands-based company. This follows the company's earlier communication dated 1st June 2026 regarding the deal. The intimation was made under SEBI Listing Regulations to NSE and BSE. No financial details of the deal were disclosed in this filing.

Likely market impact

Completes a 100% overseas acquisition, expanding the company's global footprint, though deal value remains undisclosed.